EGFR (3F5) Monoclonal Antibody

$Lane 1: Hela; Lane 2: 293T; Lane 3: Human skin lysate probed with EGFR (3F5) Monoclonal Antibody, unconjugated (bsm-52334R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.\r\n$

Lane 1: Hela; Lane 2: 293T; Lane 3: Human skin lysate probed with EGFR (3F5) Monoclonal Antibody, unconjugated (bsm-52334R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.\r\n

Flow cytometric analysis of A431 cells with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$IF(ICC) staining with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:300 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:300 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:300 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:300 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:300 in SHG-44 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:300 in SHG-44 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse brain tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse brain tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse skin tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse skin tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse liver tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse liver tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human liver tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human liver tissue incubated with EGFR (3F5) Monoclonal Antibody (bsm-52334R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Lane 1: Wild-type MC3T3 whole cell lysates; Lane 2: EGFR knockout MC3T3 whole cell lysates probed with EGFR Monoclonal Antibody, Unconjugated (bsm-52334R) at 1:500 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Wild-type MC3T3 whole cell lysates; Lane 2: EGFR knockout MC3T3 whole cell lysates probed with EGFR Monoclonal Antibody, Unconjugated (bsm-52334R) at 1:500 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

$Lane 1: Human HeLa cell lysates; Lane 2: Human MDA-MB-231 cell lysates probed with EGFR Monoclonal Antibody, Unconjugated (bsm-52334R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Human HeLa cell lysates; Lane 2: Human MDA-MB-231 cell lysates probed with EGFR Monoclonal Antibody, Unconjugated (bsm-52334R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-52334R
Product Name	EGFR (3F5) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(ICC), IHC
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein
Immunogen Range	1070-1210/1210
Clonality	Monoclonal
Clone #	3F5
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	1956
Swiss Prot	P00533
Synonyms	Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
Background	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Isoform 2 may act as an antagonist of EGF action.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC

Applications

Reactivity

Search our catalog of hundreds of thousands of products